Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where S. Meyer is active.

Publication


Featured researches published by S. Meyer.


principles and practice of constraint programming | 2006

Antidiabetic medications in overdose : a comparison of the inquiries made to a regional poisons unit regarding sulfonylureas, biguanides and insulin

M.-A. Von Mach; M. Gauer; S. Meyer; B. Omogbehin; Helmut Schinzel; Peter Herbert Kann; L. S. Weilemann

OBJECTIVE The drugs most commonly used to treat diabetes mellitus are sulfonylureas, biguanides and insulin. The most serious effects seen in overdose with these agents are hypoglycemia or lactic acidosis which may be fatal or cause cerebral defects. The present investigation analyzes inquiries made to a regional poisons unit involving overdoses with sulfonylureas, biguanides and insulin. PATIENTS AND METHODS A total of 218,070 made inquiries between 1995 and 2004 were evaluated. The inquiries were received by telephone and a standardized questionnaire was sent subsequently to the physicians calling for follow-up information. The cases were analyzed with regard to gender, age, etiology, symptoms and clinical outcome. RESULTS 263 inquiries concerning sulfonylureas (48.3% female, 49.4% male, 2.3% sex unknown, average age 39.1 +/- 26.8 years), 172 concerning biguanides (60.5% female, 37.2% male, 2.3% sex unknown, average age 41.5 +/- 24.1 years), and 191 concerning insulin (53.9% female, 41.9% male, 4.2% sex unknown, average age 44.6 +/- 16.7) were made. In cases involving sulfonylureas, the etiology was deliberate self-poisoning in 62.7% and accidental in 31.9% (biguanides 60.5% and 29.1%, insulin 85.3% and 9.4%). Using the Poisoning Severity Score, no symptoms were observed in 41.4% of the patients with sulfonylurea overdose (biguanides 40.1%, insulin 22.5%), minor symptoms in 37.6% (biguanides 32.6%, insulin 33.5%), major symptoms in 14.4% (biguanides 13.4%, insulin 26.2%) and serious symptoms in 4.6% (biguanides 12.2%, insulin 14.7%). Returned questionnaires reporting clinical outcomes showed that a full recovery occurred in most patients (sulfonylureas 97.4%, biguanides 93.0%, insulin 94.4%), cerebral defects persisted in 1.8% of the cases involving sulfonylureas (biguanides 1.5%, insulin 2.4%), and that 0.9% of the patients with sulfonylurea overdose died (biguanides 6.1%, insulin 3.6%). CONCLUSIONS Sulfonylureas were the most frequently observed medication in cases of overdose with antidiabetic agents. Insulin overdose caused the highest number of major and serious symptoms. Overdose with biguanides led to the most deaths.


Experimental and Clinical Endocrinology & Diabetes | 2010

Sarcoidosis following Cushing's syndrome: A report of two cases and review of the literature.

Schaefer S; S. Meyer; Brueck Cc; Matthias M. Weber; Luedecke D; Wagner Hj; Peter Herbert Kann

Cushings syndrome is characterized by excessive elevation of glucocorticoid concentrations. In rare cases, the treatment of Cushings syndrome may result in unmasking or aggravation of diseases responsive to glucocorticoid medication. We report two cases of sarcoidosis following Cushings syndrome. A 43 year-old male developed cutaneous sarcoidosis and mediastinal lymphadenopathy after resection of an ACTH-secreting pituitary microadenoma. A 32 year-old female showed cutaneous sarcoidosis, arthralgia, mediastinal lymphadenopathy and elevation of angiotensin-converting enzyme and interleukin 2-receptor concentrations after traumatic adrenal bleeding, which ceased formerly undiagnosed hypercortisolism caused by an adrenal adenoma. Sarcoidosis seems to be a rare sequel following the treatment of hypercortisolism. Skin affections were present and suggestive for the diagnosis in all reported cases. As some cases are probably missed when skin affections are lacking, a more frequent evaluation of patients after Cushings syndrome for the possible diagnosis of sarcoidosis might be necessary.


Endocrine-related Cancer | 2006

Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study

P H Kann; E Balakina; D. Ivan; D K Bartsch; S. Meyer; K-J Klose; Th Behr; P Langer


Deutsche Medizinische Wochenschrift | 2003

[Endosonographically controlled transluminal fine needle aspiration biopsy: diagnostic quality by cytologic and histopathologic classification].

S. Meyer; F. Bittinger; A. Keth; M.-A. Von Mach; Peter Herbert Kann


Growth Hormone & Igf Research | 2007

Short stature and decreased insulin-like growth factor I (IGF-I)/growth hormone (GH)-ratio in an adult GH-deficient patient pointing to additional partial GH insensitivity due to a R179C mutation of the growth hormone receptor

S. Meyer; M. Ipek; A. Keth; T. Minnemann; M.A. von Mach; A. Weise; J.R. Ittner; P.P. Nawroth; U. Plöckinger; Günter K. Stalla; U. Tuschy; M.M. Weber; Peter Herbert Kann


Deutsche Medizinische Wochenschrift | 2006

Die neue Rolle der Endosonographie in der Endokrinologie : Bildgebung der Nebennieren und des endokrinen Pankreas

Peter Herbert Kann; S. Meyer; A. Zielke; Peter Langer; Ivan D


Experimental and Clinical Endocrinology & Diabetes | 2007

Tumor regression in a nonfunctioning pancreatic neuroendocrine tumor during somatostatin analogue treatment

U Koehler; S. Meyer; S. Schaefer; D. Ivan; Peter Herbert Kann


Experimental and Clinical Endocrinology & Diabetes | 2008

Common insulin-like growth factor 1 (IGF-1) gene polymorphisms are not associated with the growth hormone (GH)-dose in adults with GH-deficiency

S. Meyer; U Köhler; U. Plöckinger; G. K. Stalla; Ulrich Tuschy; Peter Herbert Kann


Experimental and Clinical Endocrinology & Diabetes | 2007

Multiple endocrine neoplasia type 1 (MEN1) and quality of life

D. Ivan; J. Rosebrock; P. Langer; S. Meyer; S. Schaefer; Peter Herbert Kann


Experimental and Clinical Endocrinology & Diabetes | 2007

A case of unexplained hypercalcemia

U Koehler; Cc Brueck; S. Meyer; Lorenz C. Hofbauer; Peter Herbert Kann

Collaboration


Dive into the S. Meyer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

A. Zielke

University of Marburg

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lorenz C. Hofbauer

Dresden University of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

P H Kann

University of Marburg

View shared research outputs
Top Co-Authors

Avatar

P.P. Nawroth

University Hospital Heidelberg

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge